Filing summary
Entity and period: The supplied filing is Nanophase Technologies Corporation’s Form 10-Q for the quarter ended June 30, 2014—not a filing identified as Solesence, Inc. The financial statements are unaudited; amounts below are in thousands of dollars except per-share data.
Business context and financial results
Nanophase develops and manufactures engineered nano- and sub-micron materials for markets including personal care, coatings, polishing, plastics, diagnostics, and energy. Product sales are its primary revenue source.
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Net revenue | $2,878 | $2,683 | $5,462 | $5,662 |
| Gross profit | $1,032 | $849 | $1,739 | $1,755 |
| Gross margin | 35.9% | 31.6% | 31.8% | 31.0% |
| Operating loss | $(69) | $(461) | $(497) | $(945) |
| Net loss | $(70) | $(452) | $(499) | $(936) |
| Net loss per share | $(0.00) | $(0.02) | $(0.02) | $(0.03) |
For the six months ended June 30, 2014, operating cash use was $739, investing cash use was $114, and financing cash use was $15. Cash and cash equivalents declined by $868 to $2,408; cash, cash equivalents, and short-term investments totaled $2,438. The company reported no debt, with $26 of current capital lease obligations and no long-term lease balance. Current assets were $4,532 versus current liabilities of $1,012.
Changes versus comparable periods
- Q2 revenue increased 7% year over year, while first-half revenue decreased 4%. Product revenue followed the same pattern: Q2 rose to $2,848, but first-half product revenue fell to $5,423.
- Management attributed the Q2 improvement partly to a more balanced order pattern from its largest personal-care customer and stronger polishing orders. First-half revenue was affected by a coatings customer’s prior-year product ramp not recurring and another customer managing supply more tightly.
- First-half gross profit was nearly flat despite lower revenue, and gross margin improved modestly. Operating and net losses narrowed, primarily alongside lower research and development and selling, general and administrative costs.
- First-half research and development expense declined to $673 from $882; selling, general and administrative expense declined to $1,563 from $1,818.
Outlook, risks, and contingencies
- Management expected cash on hand and operating cash to fund its plans through the remainder of 2014. Planned capital spending for the remainder of the year was $250–$300, mainly for polishing-related equipment. No specific revenue or earnings guidance was provided.
- Management expected research and development expense to increase slightly and selling, general and administrative expense to rise slightly, but not significantly, during the remainder of 2014. It said higher production could improve overhead absorption, while margins would depend on revenue mix and volume, cost control, and the ability to pass through raw-material increases.
- Customer concentration is substantial: the largest customer represented about 68% of Q2 revenue and 74% of first-half revenue. The filing identifies BASF as the largest customer and warns that losing a major customer could materially harm results.
- BASF supply agreements include contingent rights to obtain a technology license and production equipment in specified circumstances. A key financial trigger includes trailing-12-month earnings below zero together with cash and certain investments below $1 million; the filing also describes triggers related to certain performance, covenant, insolvency, or debt-acceleration events. Cash and specified investments were about $2.4 million at quarter-end, and the company reported no debt. A trigger and BASF’s exercise of its rights could cause significant near-term revenue and capacity losses.
- Other disclosed risks include financing availability, uncertain adoption and demand, manufacturing capacity and product mix, competition and intellectual-property protection, and increases in materials or labor costs. The company reported approximately $79 million in tax-loss carryforwards, whose use may be limited and some of which may expire unused.
- Management said no material risk-factor changes had occurred since the 2013 Form 10-K, no legal proceedings were reported, and disclosure controls were effective.
Investor facts to verify
- Confirm the issuer identity: the supplied document is for Nanophase Technologies Corporation, not Solesence, Inc.
- Track revenue and receivables concentration, particularly dependence on the largest customer and BASF-related contract terms.
- Monitor cash burn, cash levels against the BASF $1 million covenant threshold, and whether planned capital spending proceeds.
- Assess whether polishing and other development initiatives translate into recurring sales and whether revenue volume improves margins.
- Review the 2013 Form 10-K for full risk-factor disclosures and details on tax-loss carryforward limitations.